temgesic 0.3 mg/ml inj. sol. i.v./i.m. amp.
eumedica pharmaceuticals gmbh - buprenorphine hydrochloride 0,32 mg/ml - eq. buprenorphine 0,3 mg/ml - solution for injection - 0,3 mg/ml - buprenorphine hydrochloride 0.32 mg/ml - buprenorphine
temgesic sublingualis 0.2 mg subl. tabl.
eumedica pharmaceuticals gmbh - buprenorphine hydrochloride 0,22 mg - eq. buprenorphine 0,2 mg - sublingual tablet - 0,2 mg - buprenorphine hydrochloride 0.22 mg - buprenorphine
orap tablets 4mg
eumedica sa winston churchill avenue, 67 be-1180 brussels, belgium - pimozide - tablet - pimozide 4 mg - psycholeptics
bactrim suspension oral
eumedica pharmaceuticals ag - sulfamethoxazole, trimethoprim - suspension oral - 200mg/5ml+ 40mg/5ml
temopen 2 g pulver zur herstellung einer injektions-/infusionslösung
temopen 1 g pulver zur herstellung einer injektions-/infusionslösung
beromun
belpharma s.a. - tasonermin - sarcoma - immunostimulants, - beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ilp).
bactrim forte tablets film-coated
f. hoffmann-la roche ltd - sulfamethoxazole, trimethoprim - tablets film-coated - 800mg+ 160mg
bactrim forte tablets
f. hoffmann-la roche ltd - sulfamethoxazole, trimethoprim - tablets - 800mg+ 160mg
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastic agents - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).